Volume 20 Issue 4
Apr.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(4): 546-549
ZHONG Chong-xia, LIU Yi-hai, FANG Qi-jun, SHA Du-juan, KANG Li-na, XU Biao, NI Jie. Prognostic value of apolipoprotein A1 in elderly patients with ischemic cardiomyopathy and heart failure[J]. Chinese Journal of General Practice, 2022, 20(4): 546-549. doi: 10.16766/j.cnki.issn.1674-4152.002397
Citation: ZHONG Chong-xia, LIU Yi-hai, FANG Qi-jun, SHA Du-juan, KANG Li-na, XU Biao, NI Jie. Prognostic value of apolipoprotein A1 in elderly patients with ischemic cardiomyopathy and heart failure[J]. Chinese Journal of General Practice, 2022, 20(4): 546-549. doi: 10.16766/j.cnki.issn.1674-4152.002397
shu

Prognostic value of apolipoprotein A1 in elderly patients with ischemic cardiomyopathy and heart failure

doi: 10.16766/j.cnki.issn.1674-4152.002397
  • 1.

    Department of Cardiology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China

Funds:

 82100398

  • Received Date: 2021-12-17
    Available Online: 2022-08-20
    Abstract
  •   Objective  To observe the level of serum apolipoprotein A1 (apoA1) in elderly patients with ischemic cardiomyopathy and heart failure, and to explore the prognostic value of serum apoA1 in elderly patients with ischemic cardiomyopathy and heart failure.  Methods  Elderly patients with ischemic cardiomyopathy and heart failure hospitalized in the Cardiology Department of Nanjing Drum Tower Hospital from March 2018 to December 2019 were selected retrospectively. The end events were followed up by telephone. The patients were divided into two groups according to whether cardiac death occurred or not. The baseline data (age, gender, BMI, etc.), serological indexes (BNP, apoA1, HDL-C, etc.) and imaging indexes (echocardiography) of different subgroups were compared.  Results  A total of 105 patients were included, of which 9 cases (8.7%) had cardiac death during follow-up. The age, gender, blood pressure, heart rate, BMI, smoking and drinking history, complications and medication history were compared between the two groups. It was found that the mortality rate of patients with higher the New York Heart Association (NYHA) grade and digoxin medication history increased (P < 0.05), but there was no significant difference in the rest between the two groups. Univariate analysis showed that the increase of BNP and globulin and the decrease of HDL-C and apoA1 were possible prognostic factors in the group of cardiac death (P < 0.05). Multivariate logistic regression analysis showed that apoA1 was an independent risk factor for cardiac death (OR < 0.001, P=0.007). The patients were divided into low value group and high value group according to the level of apoA1. It was found that the low value group had a higher level of C-reactive protein (t=3.505, P < 0.01). The ROC curve of globulin, HDL cholesterol, apoA1, BNP was drawn together, and area under ROC curve was 0.863, indicating the preferable prediction effect of the model.  Conclusion  ApoA1 is an independent risk factor for cardiac death in elderly patients with ischemic cardiomyopathy and heart failure.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    TOMASONI D, ADAMO M, LOMBARDI C M, et al. Highlights in heart failure[J]. ESC Heart Fail, 2019, 6(6): 1105-1127. doi: 10.1002/ehf2.12555
    [2]
    KATZ D, GAVIN M C. Stable ischemic heart disease[J]. Ann Intern Med, 2019, 171(3): ITC17-ITC32. doi: 10.7326/AITC201908060
    [3]
    COCHRAN B J, ONG K L, MANANDHAR B, et al. APOA1: A protein with multiple therapeutic functions[J]. Curr Atheroscler Rep, 2021, 23(3): 11. doi: 10.1007/s11883-021-00906-7
    [4]
    TONRY C, MCDONALD K, LEDWIDGE M, et al. Multiplexed measurement of candidate blood protein biomarkers of heart failure[J]. ESC Heart Fail, 2021, 8(3): 2248-2258. doi: 10.1002/ehf2.13320
    [5]
    王丽君, 郜珊珊. 血清apoA1水平与冠心病患者左室收缩功能的关系[J]. 临床心血管病杂志, 2021, 37(11): 988-991. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202111004.htm

    WANG L J, GAO S S. Relationship between serum apoA1 levels and left ventricular systolic function in patients with coronary artery disease[J]. Journal of Clinical Cardiology, 2021, 37(11): 988-991. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202111004.htm
    [6]
    韩智红, 吴学思. 缺血性左心室收缩功能障碍-心血管病医生的挑战[J]. 心肺血管病杂志, 2018, 37(5): 381-383. doi: 10.3969/j.issn.1007-5062.2018.05.001

    HAN Z H, WU X S. Ischemic left ventricular systolic dysfunction with-cardiologist challenges[J]. Journal of Cardiovascular and Pulmonary Diseases, 2018, 37(5): 381-383. doi: 10.3969/j.issn.1007-5062.2018.05.001
    [7]
    ELGENDY I Y, MAHTTA D, PEPINE C J, et al. Medical therapy for heart failure caused by ischemic heart disease[J]. Circ Res, 2019, 124(11): 1520-1535. doi: 10.1161/CIRCRESAHA.118.313568
    [8]
    茅焕豪, 叶剑飞, 郑伟峰, 等. 左西孟旦联合冻干重组人脑利钠肽对缺血性心肌病患者心室重构改善作用的研究[J]. 中华全科医学, 2021, 19(11): 1861-1863, 1950. doi: 10.16766/j.cnki.issn.1674-4152.002186

    MAO H H, YE J F, ZHENG W F, et al. Effect of levosimendan combined with lyophilised recombinant human brain natriuretic peptide on ventricular remodelling in patients with ischemic cardiomyopathy[J]. Chinese Journal of General Practice, 2021, 19(11): 1861-1863, 1950. doi: 10.16766/j.cnki.issn.1674-4152.002186
    [9]
    何新为, 陈加仕, 郭勤生. 左室射血功能与NT-proBNP对缺血性心肌病预后的预测价值研究[J]. 中国处方药, 2020, 18(2): 162-163. doi: 10.3969/j.issn.1671-945X.2020.02.093

    HE X W, CHEN J S, GUO Q S. Prognostic value of left ventricular ejection function and NT-proBNP in patients with ischemic cardiomyopathy[J]. Journal Of China Prescription Drug, 2020, 18(2): 162-163. doi: 10.3969/j.issn.1671-945X.2020.02.093
    [10]
    冯婷婷, 贾淑杰, 赵全明. 高密度脂蛋白胆固醇水平与慢性心力衰竭严重程度的相关性[J]. 心肺血管病杂志, 2018, 37(8): 735-739. doi: 10.3969/j.issn.1007-5062.2018.08.007

    FENG T T, JIA S J, ZHAO Q M. Correlationship between high density lipoprotein cholesterol levels and NYHA classification of chronic heart failure in patients[J]. Journal of Cardiovascular and Pulmonary Diseases, 2018, 37(8): 735-739. doi: 10.3969/j.issn.1007-5062.2018.08.007
    [11]
    DEGORICIJA V, POTOCNJAK I, GASTRAGER M, et al. HDL subclasses and mortality in acute heart failure patients[J]. Clin Chim Acta, 2019, 490: 81-87. doi: 10.1016/j.cca.2018.12.020
    [12]
    SPOSITO A C, CARMO H R, BARRETO J, et al. HDL-targeted therapies during myocardial infarction[J]. Cardiovasc Drugs Ther, 2019, 33(3): 371-381. doi: 10.1007/s10557-019-06865-1
    [13]
    ZANONI P, VON ECKARDSTEIN A. Inborn errors of apolipoprotein A-I metabolism: Implications for disease, research and development[J]. Curr Opin Lipidol, 2020, 31(2): 62-70. doi: 10.1097/MOL.0000000000000667
    [14]
    RICHART A L, REDDY M, KHALAJI M, et al. Apo AI nanoparticles delivered post myocardial infarction moderate inflammation[J]. Circ Res, 2020, 127(11): 1422-1436. doi: 10.1161/CIRCRESAHA.120.316848
    [15]
    ADAMO L, ROCHA-RESENDE C, PRABHU S D, et al. Reappraising the role of inflammation in heart failure[J]. Nat Rev Cardiol, 2020, 17(5): 269-285.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (352) PDF downloads(21) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return